Evidence map›Paper›PMID 42325533›Full record

ArticleFrontiers in nutrition2026

Correlation between prognostic nutritional index and oral mucositis in patients with lung adenocarcinoma treated with almonertinib: a multicenter prospective study.

Simeng Gao, Jingru Han, Zhenlong Tian, Qian Li, Linhao Xie, Min Su, Qiang Chen, Xinhai Zhu, Jianfu Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Simeng GaoDepartment of Oncology, Cancer Diagnosis and Therapy Research Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Jingru HanDepartment of Oncology, Cancer Diagnosis and Therapy Research Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Zhenlong TianDepartment of Oncology, Cancer Diagnosis and Therapy Research Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Qian LiDepartment of Oncology, Cancer Diagnosis and Therapy Research Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Linhao XieDepartment of Oncology, Cancer Diagnosis and Therapy Research Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Min SuDepartment of Oncology, Cancer Diagnosis and Therapy Research Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Qiang ChenDepartment of Oncology, Cancer Diagnosis and Therapy Research Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Xinhai ZhuDepartment of Oncology, Cancer Diagnosis and Therapy Research Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Jianfu ZhaoDepartment of Oncology, Cancer Diagnosis and Therapy Research Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral mucositis (OM) is a common adverse reaction to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and severe cases can impair patient compliance and quality of life. The prognostic nutritional index (PNI) comprehensively reflects an individual's nutritional and immune status and has been applied in lung cancer prognosis studies. However, its relationship with treatment-related OM associated with EGFR-TKI remains unclear. This study aims to investigate the correlation between PNI and the occurrence of OM in patients with lung adenocarcinoma treated with almonertinib. Methods: This study is a multicenter, prospective observational study. From May 2025 to September 2025, 14,039 patients were assessed for eligibility on the unified platform; 537 met the eligibility criteria and had complete baseline data for analysis. Baseline clinical and laboratory data were collected, and PNI was calculated as 5 × lymphocyte count (10 Results: During follow-up, 14.5% of patients developed OM. Multivariate logistic regression analysis showed that for each 1-unit increase in PNI, the risk of OM decreased by approximately 1.4% (OR = 0.986, 95% CI: 0.972-1.000). Trend analysis results indicate that patients with high PNI levels exhibit a significantly reduced risk of developing OM ( Conclusion: Low PNI levels are independently associated with a significantly increased risk of OM. As a simple, cost-effective, and readily accessible indicator, PNI holds promise as a valuable tool for early risk stratification and personalized management in patients with EGFR-mutated lung adenocarcinoma, providing guidance for optimizing targeted therapy throughout the treatment journey.

Indexed as

adverse reactionsalmonertiniblung adenocarcinomaoral mucositisprognostic nutritional index

Identifiers

PMID42325533
PMCPMC13279082

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.